LAS VEGAS, NEVADA / ACCESS Newswire / July 30, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) (“ALT5” or the “Company”), a forward-thinking financial technology firm specializing in blockchain-based payment solutions and trading infrastructure for businesses and financial institutions worldwide, today revealed a successful integration. The integration involves their institutional-grade ALT5 Prime FIX API and Fundamental Interaction, a respected provider of cutting-edge trading technology utilized by U.S. FINRA-registered broker-dealers and Alternative Trading Systems (ATSs).
This integration provides direct, streamlined, and secure FIX-protocol connectivity to the digital asset marketplace. This access is now available within the trusted infrastructure used by numerous broker-dealers and trading platforms. This represents a major leap in harmonizing conventional capital markets with institutional-level cryptocurrency trading capabilities.
“By successfully connecting with Fundamental Interaction’s Real-Time Trading System, we are empowering FINRA-regulated entities to provide a secure and compliant pathway to crypto markets, coexisting seamlessly alongside traditional equities and alternative investments,” stated Peter Tassiopoulos, Chief Executive Officer of ALT5 Sigma Corp. “This represents a readily deployable solution, allowing regulated institutions to confidently participate in digital asset trading, using the familiar tools, established workflows, and comprehensive audit trails they already depend on.”
Key Integration Features:
-
Real-time trade execution and settlement services for leading digital assets, including BTC, ETH, SOL, and others.
-
Adherence to FIX 4.4 protocol standards, facilitating efficient routing, clearing processes, and comprehensive trade surveillance.
-
Uninterrupted, 24/7 accessibility to the cryptocurrency market through a unified graphical interface, identical to that used for multi-asset equities and ATS operations.
-
Built-in Know Your Customer (KYC), Anti-Money Laundering (AML), and other regulatory compliance tools directly integrated into the trading framework.
-
Advanced risk management tools tailored to meet the specific mandates of institutional clients.
Market Perspective: Opportunities for FINRA Broker-Dealers
Within the United States, there are over 3,300 firms registered with FINRA as broker-dealers. These firms collectively manage trillions of dollars in assets and execute billions of transactions annually across equities, fixed income instruments, and alternative asset classes. According to FINRA’s most recent statistical overview1, the annual transaction volume flowing through U.S. broker-dealers exceeds $110 trillion, representing a substantial distribution and execution channel for emerging asset classes such as digital assets.
The collaboration between ALT5 and Fundamental Interaction equips these institutions with a clear and compliant method to broaden their service offerings to encompass regulated digital asset trading. This expansion can be achieved while simultaneously preserving operational efficiency and maintaining audit-ready reporting mechanisms.
“Our clientele have expressed a clear need for integrating digital assets without necessitating a complete overhaul of their existing infrastructure,” said Shawn Sloves, Chief Executive Officer of Fundamental Interaction. “Through ALT5 Sigma’s FIX API, they are now equipped to provide institutional-grade crypto execution within a familiar environment already used for managing equities and alternative investments, supported by robust compliance measures, stringent risk controls, and substantial market liquidity.”
1 Source: 2025-Industry-Snapshot.pdf
About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ: ALTS) (FRA: 5AR1) is a pioneering fintech organization dedicated to developing next-generation blockchain-based technologies. Their offerings include solutions for tokenization, trading, clearing, settlement, payments, and secure custody of digital assets. Since June 2025, the Company has been included within the Russell Microcap Growth®, Russell 3000E®, and Russell 3000E Growth® Indexes, as part of the annual Russell indexes reconstitution. The Company had previously been included in the Russell Microcap® Index since June of 2024.
Established in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is instrumental in facilitating the transition towards a modernized global financial landscape through its comprehensive suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., via its various subsidiaries, operates two core platforms: “ALT5 Pay” and “ALT5 Prime.” To date, the company has facilitated over $5 billion USD in cryptocurrency-related transactions.
ALT5 Pay is an award-winning cryptocurrency payment gateway, empowering registered and approved global merchants to accept and process cryptocurrency payments. It also provides integration capabilities through plugins compatible with WooCommerce, as well as custom checkout widgets and APIs. Merchants are provided with the flexibility to opt for automatic conversion to fiat currency or receive their payments in the form of digital assets.
ALT5 Prime represents an electronic, over-the-counter (OTC) trading environment allowing registered and approved clients to trade digital assets. Clients have the option to acquire digital assets using fiat currencies and, reciprocally, liquidate digital assets to obtain fiat. Access to ALT5 Prime is facilitated through a browser-based interface, a dedicated mobile application named “ALT5 Pro” accessible via the Apple App Store and Google Play, the ALT5 Prime FIX API, and via Broadridge Financial Solutions’ NYFIX gateway for eligible clients.
The corporation is also actively pursuing the separation of its biotech division, which will operate independently as “Alyea Therapeutics Corporation.” Through its biotechnology operations, the organization concentrates on commercializing pharmaceuticals with non-addictive analgesic characteristics for the treatment of conditions inducing chronic or severe pain. Our proprietary compound, a unique formulation of low-dose naltrexone (JAN123), is initially under development for treating Complex Regional Pain Syndrome (CRPS), a condition marked by severe, persistent pain predominantly affecting the extremities. The FDA has granted Jan123 Orphan Drug Designation for CRPS treatment.
About Fundamental Interaction
Fundamental Interaction is a premier trading infrastructure provider that offers high-performance technology solutions to broker-dealers, ATSs, and international exchanges. Their Real-Time Trading System encompasses multi-asset execution capabilities, intelligent routing mechanisms, robust risk management protocols, and FIX/REST connectivity, supporting both lit and dark venues.
Forward-Looking Statements
This announcement includes forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, projections regarding the profitability and potential growth of ALT5’s platforms and business operations. These may encompass risks related to international currency fluctuations, credit risks involving third-party entities or customers, potential liability claims stemming from ALT5’s service offerings, and technological obstacles to future growth or expansion. This release may also contain statements and links regarding the potential of JAN 101 to treat PAD, JAN 123 to treat CRPS, the anticipated timelines for commencing clinical trials, whether the FDA will permit approval of JAN 123 via a 505(b)(2) regulatory pathway, the potential for JAN 101 to rapidly disrupt the PAD market following approval, and other similar projections, including statements incorporating terms such as “continue,” “expect,” “intend,” “will,” “hope,” “should,” “would,” “may,” “potential,” and analogous expressions. Such declarations reflect the Company’s present perspective regarding future events, are intrinsically subject to risks and uncertainties, and are predicated upon a range of estimates and assumptions. While these assumptions are deemed reasonable by the Company, they remain vulnerable to significant business, economic, competitive, political, and social uncertainties, as well as unforeseen contingencies.
Numerous factors may cause the Company’s actual performance or accomplishments to diverge materially from any anticipated future results, performance levels, or achievements as expressed in this press release. These factors may include, among others, those outlined within the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these identified risks or uncertainties come to pass, or should the assumptions outlined in the sections entitled “Risk Factors” within the Company’s SEC filings underlying these forward-looking statements prove inaccurate, actual outcomes may significantly differ from those projected herein. The forward-looking statements presented herein are current as of the date of this press release, and the Company disclaims any intent or obligation to update these statements, except where mandated by applicable law. The Company cannot guarantee the accuracy of these statements, as actual results and future occurrences may differ materially from those anticipated. Individuals are therefore advised that these forward-looking statements do not constitute guarantees of future performance, and investors are cautioned against placing undue reliance on these statements due to their inherent uncertainties.
Media/Investor Relations Contact
1-888-778-7091
SOURCE: ALT5 Sigma Corp
View the original
on ACCESS Newswire